Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...

Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.